Compliance with off-label Losartan use after hip arthroscopy is poor and subsequent clinical and functional outcomes are not significant. A prospective study
Journal of Hip Preservation Surgery · 05.05.2026
DOI: 10.1093/jhps/hnag015 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hip Preservation Surgery, online erschienen am 05.05.2026. Verfasst von Caterina Nicolaou und 2 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
One of the reasons for revision surgery post-hip arthroscopy (HA) is adhesions. Losartan displays inhibitory effects on transforming growth factor beta (TGF-β) and has been used to mitigate the impact of scar tissue formation and adhesions. This study aimed to assess the compliance of patients undergoing HA with Losartan off-label use, the reasons for non-compliance, and the subsequent short-term patient-related outcomes.
Methods
A prospective clinical study evaluated compliance amongst 177 consecutive patients prescribed off-label Losartan for 2 weeks post-HA. A novel questionnaire was developed for patients to complete at their 6-week follow-up to assess compliance and identify reasons for non-compliance. Clinical and functional outcomes were assessed at 1-year follow-up and compared between Losartan-compliant and Losartan-non-compliant patients.
Results
The compliance rate was 54%. There were 14.6% (n = 14) who experienced adverse effects in the ‘compliant’ group and 13.6% (n = 11) in the ‘non-compliant’ group. The main reasons for non-compliance were avoiding side effects (55%), forgetting to take the medication (30%), and insufficient education (25%). The patient activation measure (PAM) score correlated compliance directly to a patient activation measure (P-value < 0.0001).
Conclusion
No demographic or surgical factors were predictive of adherence. The only significant association with adherance was with lower PAM scores, (95% confidence interval, P-value < 0.0001), highlighting the importance of patient education in optimizing adherence. No early differences in clinical or functional outcomes were found between the groups, raising questions about the short-term benefit of Losartan. Its favourable safety profile and potential to reduce revision risk, as reported in large-scale studies, warrant further investigation.
Zitieren
APA
Nicolaou, C., Cakic, J. N., & Pietrzak, J. R. T. (2026). Compliance with off-label Losartan use after hip arthroscopy is poor and subsequent clinical and functional outcomes are not significant. A prospective study. Journal of Hip Preservation Surgery. https://doi.org/10.1093/jhps/hnag015
Vancouver
Nicolaou C, Cakic JN, Pietrzak JRT. Compliance with off-label Losartan use after hip arthroscopy is poor and subsequent clinical and functional outcomes are not significant. A prospective study. Journal of Hip Preservation Surgery. 2026. doi:10.1093/jhps/hnag015
BibTeX
@article{Nicolaou2026,
author = {Nicolaou, Caterina and Cakic, Josip N and Pietrzak, Jurek R T},
title = {Compliance with off-label Losartan use after hip arthroscopy is poor and subsequent clinical and functional outcomes are not significant. A prospective study},
journal = {Journal of Hip Preservation Surgery},
year = {2026},
doi = {10.1093/jhps/hnag015}
}
EUVIMED